Bajaj Archna, Ihegword Andrea, Qiu Chengxiang, Small Aeron M, Wei Wei-Qi, Bastarache Lisa, Feng QiPing, Kember Rachel L, Risman Marjorie, Bloom Roy D, Birtwell David L, Williams Heather, Shaffer Christian M, Chen Jinbo, Center Regeneron Genetics, Denny Joshua C, Rader Daniel J, Stein C Michael, Damrauer Scott M, Susztak Katalin
Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Kidney Int. 2020 May;97(5):1032-1041. doi: 10.1016/j.kint.2020.01.027. Epub 2020 Feb 17.
The relationship between commonly occurring genetic variants (G1 and G2) in the APOL1 gene in African Americans and different disease traits, such as kidney disease, cardiovascular disease, and pre-eclampsia, remains the subject of controversy. Here we took a genotype-first approach, a phenome-wide association study, to define the spectrum of phenotypes associated with APOL1 high-risk variants in 1,837 African American participants of Penn Medicine Biobank and 4,742 African American participants of Vanderbilt BioVU. In the Penn Medicine Biobank, outpatient creatinine measurement-based estimated glomerular filtration rate and multivariable regression models were used to evaluate the association between high-risk APOL1 status and renal outcomes. In meta-analysis of both cohorts, the strongest phenome-wide association study associations were for the high-risk APOL1 variants and diagnoses codes were highly significant for "kidney dialysis" (odds ratio 3.75) and "end stage kidney disease" (odds ratio 3.42). A number of phenotypes were associated with APOL1 high-risk genotypes in an analysis adjusted only for demographic variables. However, no associations were detected with non-renal phenotypes after controlling for chronic/end stage kidney disease status. Using calculated estimated glomerular filtration rate -based phenotype analysis in the Penn Medicine Biobank, APOL1 high-risk status was associated with prevalent chronic/end stage kidney disease /kidney transplant (odds ratio 2.27, 95% confidence interval 1.67-3.08). In high-risk participants, the estimated glomerular filtration rate was 15.4 mL/min/1.73m; significantly lower than in low-risk participants. Thus, although APOL1 high-risk variants are associated with a range of phenotypes, the risks for other associated phenotypes appear much lower and in our dataset are driven by a primary effect on renal disease.
非裔美国人载脂蛋白L1(APOL1)基因中常见的基因变异(G1和G2)与不同疾病特征(如肾脏疾病、心血管疾病和先兆子痫)之间的关系仍然存在争议。在此,我们采用了一种先基因型后表型的全表型关联研究方法,以确定宾夕法尼亚大学医学生物样本库的1837名非裔美国参与者和范德比尔特生物样本库的4742名非裔美国参与者中与APOL1高风险变异相关的表型谱。在宾夕法尼亚大学医学生物样本库中,基于门诊肌酐测量的估计肾小球滤过率和多变量回归模型被用于评估高风险APOL1状态与肾脏结局之间的关联。在对两个队列的荟萃分析中,全表型关联研究中最强的关联是高风险APOL1变异,诊断代码对“肾透析”(优势比3.75)和“终末期肾病”(优势比3.42)具有高度显著性。在仅针对人口统计学变量进行调整的分析中,许多表型与APOL1高风险基因型相关。然而,在控制慢性/终末期肾病状态后,未检测到与非肾脏表型的关联。在宾夕法尼亚大学医学生物样本库中使用基于计算的估计肾小球滤过率的表型分析,APOL1高风险状态与普遍存在的慢性/终末期肾病/肾移植相关(优势比2.27,95%置信区间1.67 - 3.08)。在高风险参与者中,估计肾小球滤过率为15.4 mL/min/1.73m²;显著低于低风险参与者。因此,尽管APOL1高风险变异与一系列表型相关,但其他相关表型的风险似乎要低得多,并且在我们的数据集中是由对肾脏疾病的主要影响驱动的。